Stricter Labelling Norms and Standardised
Testing Fees for Medical Devices
·
Draft
Amendment:
o
Proposed
changes to Medical Devices Rules, 2017.
o
Mandatory
disclosure on product labels of sterilisation facility details, including licence
number.
·
Testing
Fee System:
o
Standardised
charges introduced:
§ Implantation tests – ₹5,000
§ Sterility tests – ₹2,000
§ Surgical sutures – ₹3,000
o
Fees
to rise 5% annually; unlisted tests priced by authorised labs.
·
Objective:
o
Improve
traceability in case of infection/device failure.
o
Ensure
uniformity in testing and strengthen regulatory oversight in the fast-growing
medical devices sector.
·
Industry
Concerns:
o
Rajiv
Nath (Association of Indian Medical Device Industry) flagged feasibility and cost
issues.
o
Fixed
fees may not reflect actual lab costs, risking delays and sustainability.
o
Compliance
costs could rise, affecting supply and prices of high-volume items (e.g., syringes).
o
Suggested
risk-based approach with stricter checks for high-risk devices.
o
Sterilisation
labelling may delay exports by 3–4 weeks.
·
Strategic
Impact:
o
Move
strengthens quality systems and accountability, but requires fine-tuning
for smooth implementation.
This
development reflects India’s push toward uniform regulation and safety in medical
devices, balancing public health priorities with industry feasibility.
[ABS
News Service/20.04.2026]
Medical
devices used every day—from syringes and surgical sutures to implants—may soon face
tighter regulation, with Centre proposing stricter labelling rules and a standardised
testing fee system aimed at improving safety and accountability. Under a draft amendment
to Medical Devices Rules, 2017, manufacturers may be required to clearly disclose
on product labels where devices are sterilised, including licence number of the
facility.
The
move is intended to improve traceability so that authorities can quickly identify
the source in case of infection or device failure. Govt has also proposed fixing
testing charges across categories. As per the draft, implantation tests could cost
Rs 5,000, sterility tests, Rs 2,000 and surgical sutures, Rs 3,000. These charges
will rise by 5% annually, while fees for tests not listed will be decided by authorised
laboratories. Officials say the changes are aimed at bringing uniformity in testing
and strengthening oversight in the fastgrowing medical
devices sector, where regulation has often been flagged as uneven.
The
industry, however, has raised concerns over feasibility and cost implications. Rajiv
Nath, forum coordinator, Association of Indian Medical Device Industry, said that
while the proposals are a step towards strengthening quality systems, they may need
to be fine-tuned for smooth implementation. “The testing fees may not fully reflect
actual lab costs, and if fixed without consulting NABL-accredited labs, it could
make testing difficult to sustain, leading to delays.
This
may increase compliance costs and put some pressure on supply and prices, especially
for high-volume items like syringes and consumables,” he said. “A riskbased approach, with stricter checks for high-risk devices,
would be more effective. The sterilisation labelling requirement also needs review
as it may delay exports by 3-4 weeks...,” the forum coordinator added.